FDA Approves Novartis’ Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)wmosley2022-04-27T15:02:21+00:00April 6th, 2022|
FDA Approves Kite’s Yescarta® (axicabtagene ciloleucel) as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)wmosley2022-04-27T15:03:57+00:00April 6th, 2022|
FDA Approves Advanced Accelerator Application’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancerwmosley2022-04-27T15:05:50+00:00March 24th, 2022|
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progressionwmosley2022-04-27T15:07:18+00:00March 22nd, 2022|
FDA Approves Bristol Myers Squibb’s Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanomawmosley2022-04-27T15:08:22+00:00March 21st, 2022|
FDA Approves AstraZeneca’s Lynparza (olaparib) as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancerwmosley2022-04-27T15:09:02+00:00March 14th, 2022|